C. Chang, J. Kelly, K. Yu, S. Mbulaiteye, A. Hildesheim et al., The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: A need for reappraisal, Virus Research, vol.143, issue.2, pp.209-230, 2009.
DOI : 10.1016/j.virusres.2009.07.005

A. Hislop, G. Taylor, D. Sauce, and A. Rickinson, Cellular Responses to Viral Infection in Humans: Lessons from Epstein-Barr Virus, Annual Review of Immunology, vol.25, issue.1, pp.587-617, 2007.
DOI : 10.1146/annurev.immunol.25.022106.141553

J. Nourse, K. Jones, and M. Gandhi, Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders: Pathogenetic Insights for Targeted Therapy, American Journal of Transplantation, vol.13, issue.Pt 1, pp.888-95, 2011.
DOI : 10.2174/092986706778521959

B. Zhang, S. Kracker, and T. Yasuda, Immune Surveillance and Therapy of Lymphomas Driven by Epstein-Barr Virus Protein LMP1 in a Mouse Model, Cell, vol.148, issue.4, pp.739-51, 2012.
DOI : 10.1016/j.cell.2011.12.031

A. Barrett and B. Savani, Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents, Leukemia, vol.104, issue.Part 1, pp.1666-72, 2006.
DOI : 10.1182/blood-2004-05-1755

J. Cohen, N. Cooper, S. Chakrabarti, K. Thomson, S. Samarasinghe et al., EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning, Leukemia & Lymphoma, vol.30, issue.2, pp.256-69, 2007.
DOI : 10.1046/j.1365-2141.2002.03992.x

K. Masjosthusmann, K. Ehlert, B. Eing, J. Roth, G. Koehler et al., Delay in B-lymphocyte recovery and function following rituximab for EBV-associated lymphoproliferative disease early post-allogeneic hematopoietic SCT, Bone Marrow Transplantation, vol.77, issue.9, pp.679-84, 2009.
DOI : 10.2169/internalmedicine.33.303

P. Dumas, A. Ruggeri, and M. Robin, Incidence and risk factors of EBV reactivation after unrelated cord blood transplantation: a Eurocord and Soci??t?? Fran??aise de Greffe de Moelle-Therapie Cellulaire collaborative study, Bone Marrow Transplantation, vol.94, issue.2, pp.253-259, 2013.
DOI : 10.1016/j.bbmt.2008.05.006

S. Servais, F. Baron, and Y. Beguin, Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning, Transfusion and Apheresis Science, vol.44, issue.2, pp.205-215, 2011.
DOI : 10.1016/j.transci.2011.01.019

S. Burrel, C. Fovet, C. Brunet, L. Ovaguimian, N. Hamm et al., Routine use of duplex real-time PCR assays including a commercial internal control for molecular diagnosis of opportunistic DNA virus infections, Journal of Virological Methods, vol.185, issue.1, pp.136-177, 2012.
DOI : 10.1016/j.jviromet.2012.05.031

S. Cesaro, A. Pegoraro, and G. Tridello, A Prospective Study on Modulation of Immunosuppression for Epstein-Barr Virus Reactivation in Pediatric Patients Who Underwent Unrelated Hematopoietic Stem-Cell Transplantation, Transplantation, vol.89, issue.12, pp.1533-1573, 2010.
DOI : 10.1097/TP.0b013e3181dd6c0a

A. Blaes, Q. Cao, J. Wagner, J. Young, D. Weisdorf et al., Monitoring and Preemptive Rituximab Therapy for Epstein-Barr Virus Reactivation after Antithymocyte Globulin Containing Nonmyeloablative Conditioning for Umbilical Cord Blood Transplantation, Biology of Blood and Marrow Transplantation, vol.16, issue.2, pp.287-91, 2010.
DOI : 10.1016/j.bbmt.2009.10.008

Z. Peric, X. Cahu, and P. Chevallier, Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation, Leukemia, vol.95, issue.6, pp.932-940, 2011.
DOI : 10.1038/sj.bmt.1704442

A. Lurati, M. Marrazza, K. Re, and M. Scarpellini, Relationship between NK cell activation and clinical response in rheumatoid arthritis treated with rituximab, Int J Biomed Sci, vol.5, pp.92-97, 2009.

S. Veeramani, S. Wang, C. Dahle, S. Blackwell, L. Jacobus et al., Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism, Blood, vol.10, issue.1, pp.3347-3356, 2011.
DOI : 10.1158/1535-7163.MCT-10-0385

B. Foley, S. Cooley, M. Verneris, M. Pitt, J. Curtsinger et al., Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function, Blood, vol.127, issue.2, pp.2665-74, 2012.
DOI : 10.1016/j.imlet.2009.09.009

S. Krams and O. Martinez, Epstein???Barr virus, rapamycin, and host immune responses, Current Opinion in Organ Transplantation, vol.13, issue.6, pp.563-571, 2008.
DOI : 10.1097/MOT.0b013e3283186ba9

F. Pietersma, E. Piriou, and D. Van-baarle, Immune surveillance of EBV-infected B cells and the development of non-Hodgkin lymphomas in immunocompromised patients, Leukemia & Lymphoma, vol.73, issue.6, pp.1028-1069, 2008.
DOI : 10.1111/j.1600-065X.1997.tb00983.x

D. Martorelli, E. Muraro, A. Merlo, R. Turrini, D. Fa-e et al., Exploiting the Interplay between Innate and Adaptive Immunity to Improve Immunotherapeutic Strategies for Epstein-Barr-Virus-Driven Disorders, Clinical and Developmental Immunology, vol.117, issue.23, pp.1-19, 2012.
DOI : 10.1128/JVI.00923-10

J. Benjamin, S. Gill, and R. Negrin, Biology and clinical effects of natural killer cells in allogeneic transplantation, Current Opinion in Oncology, vol.22, issue.2, pp.130-137, 2010.
DOI : 10.1097/CCO.0b013e328335a559

M. Cooper, T. Fehniger, and M. Caligiuri, The biology of human natural killer-cell subsets, Trends in Immunology, vol.22, issue.11, pp.633-673, 2001.
DOI : 10.1016/S1471-4906(01)02060-9

T. Fehniger, M. Cooper, G. Nuovo, M. Cella, F. Facchetti et al., CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity, Blood, vol.2, issue.10, pp.3052-3059, 2003.
DOI : 10.1038/ni1001-917

J. Miller, Y. Soignier, and A. Panoskaltsis-mortari, Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer, Blood, vol.105, issue.8, pp.3051-3058, 2005.
DOI : 10.1182/blood-2004-07-2974

M. Berg, A. Lundqvist, P. Mccoy, . Jr, L. Samsel et al., Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells, Cytotherapy, vol.11, issue.3, pp.341-55, 2009.
DOI : 10.1080/14653240902807034

S. Charni, J. Aguilo, J. Garaude, G. De-bettignies, C. Jacquet et al., ERK5 Knockdown Generates Mouse Leukemia Cells with Low MHC Class I Levels That Activate NK Cells and Block Tumorigenesis, The Journal of Immunology, vol.182, issue.6, pp.3398-405, 2009.
DOI : 10.4049/jimmunol.0803006

URL : https://hal.archives-ouvertes.fr/hal-02194092

M. Wills, O. Ashiru, M. Reeves, G. Okecha, J. Trowsdale et al., Human Cytomegalovirus Encodes an MHC Class I-Like Molecule (UL142) That Functions to Inhibit NK Cell Lysis, The Journal of Immunology, vol.175, issue.11, pp.7457-65, 2005.
DOI : 10.4049/jimmunol.175.11.7457

E. Seidel, A. Glasner, and O. Mandelboim, Virus-mediated inhibition of natural cytotoxicity receptor recognition, Cellular and Molecular Life Sciences, vol.9, issue.2, pp.3911-3931, 2012.
DOI : 10.1016/j.chom.2011.01.008

B. Swift, B. Williams, Y. Kosaka, X. Wang, J. Medin et al., Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model, Haematologica, vol.97, issue.7, pp.1020-1028, 2012.
DOI : 10.3324/haematol.2011.054254

T. Granot, L. Venticinque, J. Tseng, and D. Meruelo, Activation of Cytotoxic and Regulatory Functions of NK Cells by Sindbis Viral Vectors, PLoS ONE, vol.16, issue.6, 2011.
DOI : 10.1371/journal.pone.0020598.s003

M. Boeckh, W. Leisenring, S. Riddell, R. Bowden, M. Huang et al., Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity, Blood, vol.101, issue.2, pp.407-421, 2003.
DOI : 10.1182/blood-2002-03-0993

J. Rubnitz, H. Inaba, R. Ribeiro, S. Pounds, B. Rooney et al., NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia, Journal of Clinical Oncology, vol.28, issue.6, pp.995-1004, 2010.
DOI : 10.1200/JCO.2009.24.4590